Clinical spectrum of γδ+ T cell LGL leukemia:: Analysis of 20 cases

被引：51

作者：

Bourgault-Rouxel, A. S. ^{[1
]}

Loughran, T. P., Jr. ^{[3
]}

Zambello, R. ^{[4
]}

Epling-Burnette, P. K. ^{[5
]}

Semenzato, G. ^{[4
]}

Donadieu, J. ^{[6
]}

Amiot, L. ^{[2
]}

Fest, T. ^{[2
]}

Lamy, T. ^{[1
]}

机构：

[1] Serv Hematol Clin, Rennes, France

[2] Lab Hematol Immnnol & Therapie Cellulaire, Rennes, France

[3] Penn State Canc Inst, Hershey, PA USA

[4] Univ Padua, Sch Med, Hematol & Clin Immunol Branch, Dept Clin & Expt Med, Padua, Italy

[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[6] Hop Trousseau, Serv Hemato Oncol Pediat, F-75571 Paris, France

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 01期

基金：

美国国家卫生研究院;

关键词：

LGL leukemia; TCR-gamma delta; TCR alpha beta;

D O I：

10.1016/j.leukres.2007.04.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

We report on the clinico-biological characteristics of 20 cases of gamma delta T cell large granular lymphocyte (LGL) leukemia. All the data were compared to that of 196 cases with up T cell subtype, which represents the majority of T cell LGL leukemias. Clinical findings were quite similar in the two groups regarding age, sex ratio, recurrent infections, and association with auto-immune diseases especially rheumatoid arthritis. gamma delta LGL predominantly expressed a CD3+/CD4-/CD8+/CD16+/CD57+phenotype, in 50% of cases. Clinical outcome was favorable for these patients with overall survival of 85% at 3 years. Fifty percent of gamma delta patients required treatment and the response to therapy was estimated at 55%. gamma delta and alpha beta T cell LGL leukemia harbor a very similar clinico-biological behavior and represent part of an antigen-driven T cell lymphoproliferation. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：45 / 48

页数：4

共 25 条

[1]

DHODAPKAR MV, 1994, BLOOD, V84, P1620

[2]

MALIGNANT T-GAMMA/DELTA LYMPHOPROLIFERATIVE DISEASE WITH NATURAL-KILLER LYTIC ACTIVITY [J].